Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

Elmar A. Joura(Medical University of Vienna), Sepp Leodolter(Medical University of Vienna), Mauricio Hernández‐Ávila(Instituto Nacional de Salud Pública), Cosette M. Wheeler(University of New Mexico), Gonzalo Pérez, Laura A. Koutsky(University of Washington), Suzanne M. Garland(University of Melbourne), Diane M. Harper(Dartmouth College), Grace Tang(University of Hong Kong), Daron G. Ferris(Augusta University), Marc Steben(Institut National de Santé Publique du Québec), Ronald W. Jones, Janine T. Bryan(United States Military Academy), Frank J. Taddeo(United States Military Academy), Oliver Bautista(United States Military Academy), Mark T. Esser(United States Military Academy), Heather L. Sings(United States Military Academy), Micki Nelson(United States Military Academy), John W. Boslego(United States Military Academy), Carlos Sattler(United States Military Academy), Eliav Barr(United States Military Academy), Jorma Paavonen(Helsinki University Hospital)
The Lancet
May 1, 2007
Cited by 580

Abstract


Related Papers

No related papers found

Powered by citation graph analysis